PMID: 590309Nov 14, 1977

The pharmacokinetics of cefuroxime after intravenous injection

European Journal of Clinical Pharmacology
P E Gower, C H Dash

Abstract

Cefuroxime, a new cephalosporin antibiotic which is stable to most beta-lactamases produced by gram-negative bacteria, was given by bolus intravenous injection to six volunteers in doses of 500 mg and 750 mg. The concentrations of cefuroxime in serum and urine were measured at pre-determined times after injection and the data analysed by a two-compartment open system model. A serum concentration of 8 microgram/ml was exceeded for 100.3 min (+/- 18.3) after a 500 mg dose and for 144.5 min (+/- 19.8) after 750 mg. The ultimate serum half-life was 1.1 h. Excretion of cefuroxime in the urine was almost complete in 24 h, the clearance being 150 ml/min/1.73m2. About 45% was excreted through the renal tubules. The injections were well tolerated and no changes in haematological or biochemical values were seen. The resulting data are compared with those published for some other cephalosporins. It is concluded that the favourable pharmacokinetics, especially the high concentrations of unbound cefuroxime in the serum, are likely to aid effective therapy of human infection caused by sensitive bacteria.

References

May 1, 1977·The Journal of Antimicrobial Chemotherapy·C S GoodwinA D Goldberg
Jan 1, 1976·The Journal of Antibiotics·C H O'CallaghanP W Muggleton
May 1, 1976·Antimicrobial Agents and Chemotherapy·R D Foord
Jan 1, 1976·Antimicrobial Agents and Chemotherapy·B R MeyersS Z Hirschman
Jan 1, 1976·Antimicrobial Agents and Chemotherapy·I W FongW M Kirby
Mar 1, 1976·Antimicrobial Agents and Chemotherapy·C H O'CallaghanJ E Thornton
Oct 1, 1973·The Journal of Infectious Diseases·W M Kirby, C Regamey
Apr 1, 1974·Clinical Pharmacology and Therapeutics·P G WellingC M Kunin
Apr 1, 1967·Journal of Pharmaceutical Sciences·J G Wagner, J I Northam
Sep 1, 1974·Antimicrobial Agents and Chemotherapy·W BrumfittJ N Gilchrist

Citations

Mar 1, 1992·Prenatal Diagnosis·B R BenacerrafF R Bieber
Jan 1, 1983·European Journal of Clinical Pharmacology·R A WalstadK J Berg
Aug 1, 1979·Antimicrobial Agents and Chemotherapy·R LüthyW Siegenthaler
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·J E ConnorsT R Young
Jun 10, 1978·British Medical Journal·S Selwyn
Apr 3, 2012·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Fumi SuzukiHiroyasu Ogata
Jan 1, 1981·Scandinavian Journal of Infectious Diseases·A NetlandE Andrew
Jan 1, 1980·Current Medical Research and Opinion·A P RobertsR B Sykes
Aug 29, 2006·British Journal of Clinical Pharmacology·Anders VibergMarie Sandström
Jul 31, 2007·Journal of Clinical Pharmacology·Matts KågedalOlof Borgå
May 20, 1978·Lancet·S Selvyn
May 20, 1978·Lancet·P G Swift, D W Stevens
Mar 31, 2004·Rapid Communications in Mass Spectrometry : RCM·Anders VibergBritt Jansson
Jun 1, 1986·The Australian and New Zealand Journal of Psychiatry·E GordonR A Meares
Feb 18, 2017·Clinical Pharmacokinetics·Anton IvanyukThierry Buclin
Mar 1, 1985·Drug Intelligence & Clinical Pharmacy·T A Tartaglione, R E Polk
Sep 6, 2019·British Journal of Clinical Pharmacology·Christer RimmlerGeorg Hempel
Oct 7, 2020·Antimicrobial Agents and Chemotherapy·J LanoiseléeE Ollier
Sep 13, 2019·Anaesthesia Critical Care & Pain Medicine·Clément BoidinSandrine Lefeuvre

Related Concepts

Cephalosporanic Acids
Tetrahydrofurans
Intravenous Injections

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Pediculosis pubis

Pediculosis pubis is a disease caused by a parasitic insect known as Pthirus pubis, which infests human pubic hair, as well as other areas with hair including eye lashes. Here is the latest research.

Rh Isoimmunization

Rh isoimmunization is a potentially preventable condition that occasionally is associated with significant perinatal morbidity or mortality. Discover the latest research on Rh Isoimmunization here.

Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

Enzyme Evolution

This feed focuses on molecular models of enzyme evolution and new approaches (such as adaptive laboratory evolution) to metabolic engineering of microorganisms. Here is the latest research.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

Alignment-free Sequence Analysis Tools

Alignment-free sequence analyses have been applied to problems ranging from whole-genome phylogeny to the classification of protein families, identification of horizontally transferred genes, and detection of recombined sequences. Here is the latest research.